Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

被引：44
|
作者：
Egeberg, Alexander [1 ]
机构：
[1] Herlev & Gentofte Hosp, Copenhagen, Denmark
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2016年 / 375卷 / 21期
关键词：
INFLAMMATORY-BOWEL-DISEASE;
D O I：
10.1056/NEJMc1610828
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2101 / 2102
页数：2
相关论文
共 50 条
  • [1] Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
    Gordon, K. B.
    Blauvelt, A.
    Papp, K. A.
    Langley, R. G.
    Luger, T.
    Ohtsuki, M.
    Reich, K.
    Amato, D.
    Ball, S. G.
    Braun, D. K.
    Cameron, G. S.
    Erickson, J.
    Konrad, R. J.
    Muram, T. M.
    Nickoloff, B. J.
    Osuntokun, O. O.
    Secrest, R. J.
    Zhao, F.
    Mallbris, L.
    Leonardi, C. L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04): : 345 - 356
  • [2] Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis Reply
    Gordon, Kenneth B.
    Colombel, Jean-Frederic
    Hardin, Dana S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (21): : 2102 - 2102
  • [3] Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium
    Carmona-Rocha, Elena
    Puig, Lluis
    IMMUNOTHERAPY, 2023, 15 (15) : 1209 - 1225
  • [4] Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
    Ren, Vicky
    Dao, Harry, Jr.
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2013, 6 : 75 - 80
  • [5] Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis
    Egeberg, Alexander
    Bryld, Lars Erik
    Skov, Lone
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (01) : 173 - 178
  • [6] Efficacy and Safety of Ixekizumab in Pediatric Patients with Moderate-to-Severe Plaque Psoriasis
    Paller, Amy
    Seyger, Marieke
    Alejandro Magarinos, Gabriel
    Bagel, Jerry
    Keller, Stuart
    Capriles, Claudia Rodriguez
    Gallo, Gaia
    Edson-Heredia, Emily
    Li, Lingnan
    Xu, Wen
    Papp, Kim
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 17 - 17
  • [7] Comment on "Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis"
    Lebwohl, Mark G.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (06) : E377 - E377
  • [8] Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis
    Vu, Trang T.
    Gooderham, Melinda
    Papp, Kim
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (11) : 1423 - 1433
  • [9] Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis Analysis of Results From 3 Randomized Phase 3 Clinical Trials
    Armstrong, April W.
    Lynde, Charles W.
    McBride, Sandy R.
    Stahle, Mona
    Edson-Heredia, Emily
    Zhu, Baojin
    Amato, David
    Nikai, Enkeleida
    Yang, Fan Emily
    Gordon, Kenneth B.
    JAMA DERMATOLOGY, 2016, 152 (06) : 661 - 669
  • [10] Reply to: "Comment on 'Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis"'
    Egeberg, Alexander
    Bryld, Lars Erik
    Skov, Lone
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (06) : E379 - E379
12345